V. Kulasingam and E. P. Diamandis, Strategies for discovering novel cancer biomarkers through utilization of emerging technologies, Nat Clin Pract Oncol, vol.5, pp.588-99, 2008.

J. E. Mcdermott, J. Wang, H. Mitchell, B. J. Webb-robertson, R. Hafen et al., Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery, Expert Opin Med Diagn, vol.7, pp.327-371, 2004.

K. J. Brown, C. A. Formolo, H. Seol, R. L. Marathi, S. Duguez et al., Advances in the proteomic investigation of the cell secretome, Expert Rev Proteomics, vol.9, pp.337-382, 2012.

M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach, Mol Cell Proteomics, vol.5, pp.157-71, 2006.

M. De-wit, H. Kant, S. R. Piersma, T. V. Pham, S. Mongera et al., Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling, J Proteomics, vol.99, pp.26-39, 2014.

H. Haslene-hox, O. Tenstad, and H. Wiig, Interstitial fluid-a reflection of the tumor cell microenvironment and secretome, Biochim Biophys Acta, vol.1834, pp.2336-2382, 2013.

T. B. Schaaij-visser, M. De-wit, S. W. Lam, and C. R. Jimenez, The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context, Biochim Biophys Acta, vol.1834, pp.2242-58, 2013.

J. Korf, K. D. Huinink, and G. A. Posthuma-trumpie, Ultraslow microdialysis and microfiltration for in-line, on-line and off-line monitoring, Trends Biotechnol, vol.28, pp.150-158, 2010.

C. M. Huang, T. Nakatsuji, Y. T. Liu, and Y. Shi, In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome, Recent Pat Anticancer Drug Discov, vol.3, pp.48-54, 2008.

C. M. Huang, H. N. Ananthaswamy, S. Barnes, Y. Ma, M. Kawai et al., Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses, Proteomics, vol.6, pp.6107-6123, 2006.

C. Lasser, Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicle, Expert Opin Biol Ther, vol.15, pp.103-120, 2015.

R. Nedaeinia, M. Manian, M. H. Jazayeri, M. Ranjbar, R. Salehi et al., Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer, Cancer Gene Ther, 2016.

E. Heitzer, P. Ulz, and J. B. Geigl, Circulating tumor DNA as a liquid biopsy for cancer, Clin Chem, vol.61, pp.112-135, 2015.

S. H. Lim, K. J. Spring, P. De-souza, S. Mackenzie, and L. Bokey, Circulating tumour cells and circulating nucleic acids as a measure of tumour dissemination in non-metastatic colorectal cancer surgery, Eur J Surg Oncol, vol.41, pp.309-323, 2015.

P. Benatti, R. Gafa, D. Barana, M. Marino, A. Scarselli et al., Microsatellite instability and colorectal cancer prognosis, Clin Cancer Res, vol.11, pp.8332-8372, 2005.

L. F. Surrey, M. Luo, F. Chang, and M. M. Li, The genomic era of clinical oncology: integrated genomic analysis for precision cancer care, Cytogenet Genome Res, 2016.

A. S. Gargis, L. Kalman, D. P. Bick, C. Da-silva, D. P. Dimmock et al., Good laboratory practice for clinical next-generation sequencing informatics pipelines, Nat Biotechnol, vol.33, pp.689-93, 2015.

R. Luthra, H. Chen, S. Roy-chowdhuri, and R. R. Singh, Nextgeneration sequencing in clinical molecular diagnostics of cancer: advantages and challenges, Cancers (Basel), vol.7, pp.2023-2059, 2015.

C. H. Johnson, J. Ivanisevic, and G. Siuzdak, Metabolomics: beyond biomarkers and towards mechanisms, Nat Rev Mol Cell Biol, vol.17, pp.451-460, 2016.

N. Mcgranahan and C. Swanton, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, vol.27, pp.15-26, 2015.

J. Cox, M. Y. Hein, C. A. Luber, I. Paron, N. Nagaraj et al., Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ, Mol Cell Proteomics, vol.13, pp.2513-2539, 2014.

A. Blomme, B. Costanza, P. De-tullio, M. Thiry, G. Van-simaeys et al., Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer, Oncogene, 2016.

A. I. Saeed, N. K. Bhagabati, J. C. Braisted, W. Liang, V. Sharov et al., TM4 microarray software suite, Methods Enzymol, vol.411, issue.06, pp.11009-11014, 2006.

A. Blomme, K. Fahmy, O. Peulen, B. Costanza, M. Fontaine et al., Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes, Oncotarget, 2016.

N. Bovy, B. Blomme, P. Freres, S. Dederen, O. Nivelles et al., Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer, Oncotarget, vol.6, pp.10253-66, 2015.

O. Buhard, N. Suraweera, A. Lectard, A. Duval, and R. Hamelin, Quasimonomorphic mononucleotide repeats for highlevel microsatellite instability analysis, Dis Markers, vol.20, pp.251-258, 2004.

S. Ogino, T. Kawasaki, M. Brahmandam, L. Yan, M. Cantor et al., Sensitive sequencing method for KRAS mutation detection by Pyrosequencing, J Mol Diagn, vol.7, issue.10, pp.60571-60576, 2005.